SUPPLY AGREEMENT AIMED FOR CANADIAN AND EUROPEAN MEDICAL MARKETS
TORONTO, Aug. 2, 2018 /CNW/ - Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF) (the "Company" or "Pure Global"), a vertically integrated growth-oriented life sciences cannabis company, is pleased to announce that it has signed a letter of intent with Vancouver based Isodiol International Inc. (CSE: ISOL; OTC: ISOLF; FSE: LB6A.F) ("Isodiol") for the ongoing supply of pharmaceutical and nutraceutical grade Cannabidiol (CBD) isolates, and other potential products.
Upon the successful importation and product testing of an initial trial order of raw CBD isolate, Pure Global and Isodiol intend to establish a Definitive Supply Agreement for the ongoing supply of CBD isolate and intends to explore additional means of collaborating together.
"We're excited to secure this pharmaceutical grade source of U.K. manufactured CBD from Isodiol at a time when new local British and regional European opportunities are presenting themselves by the day," said Pure Global President & CEO, Malay Panchal. "Notwithstanding the growing demand for CBD in Canada and our plans for pharma and nutraceutical grade imports, we call ourselves 'Global' for a reason. This is the first of a number of strategic initiatives which will help propel our international vision forward."
As a GMP certified facility, Isodiol's subsidiary BSPG Laboratories LTD. has received government approval from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA), in accordance with The Human Medicines Regulations 2012 (SI 2012/1916), for the manufacturing of CBD under certificate number: UK API 48727.
About Pure Global Cannabis
Pure Global Cannabis Inc. (TSXV: PURE) (OTC: PRCNF) is a vertically integrated growth-oriented life sciences cannabis company led by experienced pharma-industry, horticultural, and supply chain experts. The Company's wholly-owned subsidiary, PureSinse Inc., is a licensed producer under Canada'sAccess to Cannabis for Medical Purposes Regulations ("ACMPR") focused on producing cannabis products for medical, wellness, and future legal adult recreational use.
Isodiol International Inc.(CSE: ISOL; OTC: ISOLF; FSE: LB6A.F) is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced April 26, 2018.
This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global's future plans and intentions. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Pure Global Cannabis Inc.
For further information: regarding Pure Global, please contact: Stephen Pynn, VP Corporate Development, Telephone: 1-866-899-PURE (7873), E-mail: [email protected]; Malay (Mel) Panchal, President & CEO, Telephone: 1-866-899-PURE (7873), E-mail: [email protected]